JP5184511B2 - 新しい結晶形態のラミブジン - Google Patents

新しい結晶形態のラミブジン Download PDF

Info

Publication number
JP5184511B2
JP5184511B2 JP2009506041A JP2009506041A JP5184511B2 JP 5184511 B2 JP5184511 B2 JP 5184511B2 JP 2009506041 A JP2009506041 A JP 2009506041A JP 2009506041 A JP2009506041 A JP 2009506041A JP 5184511 B2 JP5184511 B2 JP 5184511B2
Authority
JP
Japan
Prior art keywords
lamivudine
crystal
pharmaceutical composition
cis
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009506041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009534373A5 (enExample
JP2009534373A (ja
Inventor
ギリジ・パル・シン
ダナンジャイ・スリヴァスタヴァ
マンミート・ブリジキショレ・サイニ
プリテシュ・ラメシュバイ・ウパディアイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of JP2009534373A publication Critical patent/JP2009534373A/ja
Publication of JP2009534373A5 publication Critical patent/JP2009534373A5/ja
Application granted granted Critical
Publication of JP5184511B2 publication Critical patent/JP5184511B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2009506041A 2006-04-18 2007-02-09 新しい結晶形態のラミブジン Expired - Fee Related JP5184511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN347KO2006 2006-04-18
IN347/KOL/2006 2006-04-18
PCT/IN2007/000047 WO2007119248A1 (en) 2006-04-18 2007-02-09 A novel crystalline form of lamivudine

Publications (3)

Publication Number Publication Date
JP2009534373A JP2009534373A (ja) 2009-09-24
JP2009534373A5 JP2009534373A5 (enExample) 2010-04-02
JP5184511B2 true JP5184511B2 (ja) 2013-04-17

Family

ID=37969898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009506041A Expired - Fee Related JP5184511B2 (ja) 2006-04-18 2007-02-09 新しい結晶形態のラミブジン

Country Status (10)

Country Link
US (1) US8158607B2 (enExample)
EP (1) EP2007758B1 (enExample)
JP (1) JP5184511B2 (enExample)
AT (1) ATE485292T1 (enExample)
AU (1) AU2007237818B2 (enExample)
CA (1) CA2649796A1 (enExample)
DE (1) DE602007009957D1 (enExample)
ES (1) ES2357159T3 (enExample)
WO (1) WO2007119248A1 (enExample)
ZA (1) ZA200809820B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
WO2009069014A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Amorphous lamivudine and its preparation
BRPI0820222A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Forma i cristalina estável de lamivudina e processo de preparação
WO2009116055A1 (en) * 2008-03-17 2009-09-24 Lupin Limited Lamivudine : zidovudine : water 1 : 1 : 1 cocrystal
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
US8536151B2 (en) 2008-09-01 2013-09-17 Hetero Research Foundation Process for preparing lamivudine polymorph form
EP2435052B1 (en) * 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
DK2488516T3 (en) 2009-10-14 2015-05-26 Mylan Lab Ltd Method of producing lamivudine and novel salts in the preparation thereof
AU2011215878A1 (en) 2010-02-12 2012-08-09 Merck Sharp & Dohme Corp. Preparation of lamivudine Form I
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CA2898092A1 (en) * 2013-02-07 2014-08-14 Tobira Therapeutics, Inc. Lamivudine salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine

Also Published As

Publication number Publication date
EP2007758B1 (en) 2010-10-20
AU2007237818B2 (en) 2012-09-27
ZA200809820B (en) 2010-02-24
AU2007237818A1 (en) 2007-10-25
JP2009534373A (ja) 2009-09-24
DE602007009957D1 (de) 2010-12-02
CA2649796A1 (en) 2007-10-25
ATE485292T1 (de) 2010-11-15
US20090281053A1 (en) 2009-11-12
US8158607B2 (en) 2012-04-17
WO2007119248A1 (en) 2007-10-25
EP2007758A1 (en) 2008-12-31
ES2357159T3 (es) 2011-04-19

Similar Documents

Publication Publication Date Title
JP5184511B2 (ja) 新しい結晶形態のラミブジン
JP2020183408A (ja) ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
CN101243066B (zh) 甲磺酸伊马替尼的δ和ε晶形
EP2909191B1 (en) Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
ES2562843T3 (es) Forma IV de clorhidrato de ivabradina
JP2024095697A (ja) Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態
JP2014074067A (ja) メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形
JP2007528883A (ja) 新規なアルキル含有５−アシルインドリノン、その製法及びその医薬品としての使用
CN110831930B (zh) 杂环亚基乙酰胺衍生物的晶体
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
CN104284897B (zh) 替卡格雷晶型及其制备方法和用途
JP7168447B2 (ja) ビラスチンの結晶形態及びそれらの調製方法
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
KR100830002B1 (ko) 시부트라민의 무기산염
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
JP2007528884A (ja) 新規なシクロアルキル含有５−アシルインドリノン、その製法及びその医薬品としての使用
KR20060080818A (ko) 시부트라민의 술폰산염
JP5530369B2 (ja) 新規な結晶形
IL167659A (en) Crystalline sibutramine methanesulfonate hemihydrate, pharmaceutical compositions containing the same and methods for the preparation thereof
EP2238108B1 (en) Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
JP2023115903A (ja) ロスバスタチンアリルエステルの結晶形態
KR101120120B1 (ko) 무정형 아데포비아 디피복실을 포함하는 약학 조성물 및 이의 제조 방법
JP2008526828A (ja) 逆転写酵素モジュレーターとしてのイミダゾール誘導体
KR20130033243A (ko) 아데포비어 디피복실의 공결정
JP2004529870A (ja) 抗糖尿病薬としてのチアゾリジンジオンの新規塩およびその多形体ならびにその製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130116

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees